Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase…
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
Long-term continuous OGSIVEO treatment for up to 4 years was associated with…
FDA Approves Expanded Indication for UZEDY (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy…
FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: U.S. POINTER STUDY SHOWS STRUCTURED LIFESTYLE PROGRAM TARGETING MULTIPLE RISK FACTORS IMPROVES COGNITION IN OLDER ADULTS AT RISK OF COGNITIVE DECLINE
Key Takeaways Two lifestyle interventions in U.S. POINTER improved cognition in older…
EURneffy approved as the first needle-free anaphylaxis treatment of adults and children in the UK
Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the…
First market launch of the adrenaline nasal spray, EURneffy, for treatment of adults and children in Germany
ALK (ALKB:DC / OMX: ALK B) today announced the first market launch…
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed…
New Survey Finds Younger Adults, More Women Seeking Treatment for Hair Loss
Manageable number of monthly hair restoration surgeries illustrates ISHRS members' hands-on, expert approach…
